Obesity and insulin resistance: Effects on cardiac structure, function, and substrate metabolism

Current Hypertension Reports

Volumn 8, Issue 6, 2006, Pages 451-456

  Peterson, Linda R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CANNABINOID RECEPTOR ANTAGONIST; DEXFENFLURAMINE; FATTY ACID; FENFLURAMINE; INSULIN; LEPTIN; NEUROHORMONE; PROTEIN KINASE B; ROSIGLITAZONE;

BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CORONARY ARTERY DISEASE; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; FREQUENCY ANALYSIS; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE OXYGEN CONSUMPTION; HEMODYNAMICS; HUMAN; INSULIN RESISTANCE; LUNG DISEASE; MOLECULAR MECHANICS; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PLASMA VOLUME; POSITRON EMISSION TOMOGRAPHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

ANIMALS; CARDIAC OUTPUT; CARDIOMYOPATHIES; COMORBIDITY; ENERGY METABOLISM; HUMANS; INSULIN RESISTANCE; MYOCARDIUM; OBESITY; VENTRICULAR REMODELING; WEIGHT LOSS;

EID: 33751558777     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0022-y     Document Type: Review

References (50)

1. Yach D, Stuckler D, Brownell KD: Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2006, 12:62-66.
2. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
3. Kenchaiah S, Evans JC, Levy D, et al.: Obesity and the risk of heart failure. N Engl J Med 2002, 347:305-313.
4. Kannel WB, Hjortland M, Castelli WP: Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974, 34:29-34.
5. Hamby R, Zoneraich S, Sherman L: Diabetic cardiomyopathy. JAMA 1974, 229:1749-1754.
6. Rodrigues B, McNeill JH: The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 1992, 26:913-922.
7. Finck BN, Han X, Courtois M, et al.: A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 2003, 100:1226-1231.
8. Messerli FH, Sundgaard-Riise K, Reisin E, et al.: Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med 1983, 74:808-812.
9. Alpert MA: Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001, 321:225-236.
10. Peterson LR, Waggoner AD, Schechtman KB, et al.: Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 2004, 43:1399-1404.
11. Mensah GA, Treiber FA, Kapuku GK, et al.: Patterns of body fat deposition in youth and their relation to left ventricular markers of adverse cardiovascular progonosis. Am J Cardiol 1999, 84:583-588.
12. Ganau A, Devereux RB, Roman MJ, et al.: Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992, 19:1550-1558.
13. Alpert MA, Lambert CR, Panayiotou H, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 1995, 76:1194-1197.
14. Wong CY, O'Moore-Sullivan T, Leano R, et al.: Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004, 110:3081-3087.
15. Ahmed Q, Chung-Park M, Tomashefski JF Jr: Cardiopulmonary pathology in patients with sleep apnea/obesity hypoventilation syndrome. Hum Patbol 1997, 28:264-269.
16. Gates PE, Gentile CL, Seals DR, Christou DD: Adiposity contributes to differences in left ventricular structure and diastolic function with age in healthy men. J Clin Endocrinol Metab 2003, 88:4884-4890.
17. Carabello BA, Gittens L: Cardiac mechanics and function in obese normotensive persons with normal coronary arteries. Am J Cardiol 1987, 59:469-473.
18. Palmieri V, de Simone G, Arnett DK, et al.: Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study). Am J Cardiol 2001, 88:1163-1168.
19. Collis T, Devereux RB, Roman MJ, et al.: Relations of stroke volume and cardiac output to body composition: the strong heart study. Circulation 2001, 103:820-825.
20. Belke DD, Betuing S, Tuttle MJ, et al.: Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002, 109:629-639.
21. Shiojima I, Yefremashvili M, Luo Z, et al.: Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J Biol Chem 2002, 277:37670-37677.
22. Sasson Z, Rasooly Y, Bhesania T, Rasooly I: Insulin resistance is an important determinant of left ventricular mass in the obese. Circulation 1993, 88(4 Pt 1):1431-1436.
23. Vaccaro O, Cardoni O, Cuomo V, et al.: Relationship between plasma insulin and left ventricular mass in normotensive participants of the Gubbio Study. Clin Endocrinol (Oxf) 2003, 58:316-322.
24. Liao Y, Takashima S, Maeda N, et al.: Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005, 67:705-713.
25. Ingelsson E, Riserus U, Berne C, et al.: Adiponectin and risk of congestive heart failure. JAMA 2006, 295:1772-1774.
26. Cassis LA, Fettinger MJ, Roe AL, et al.: Characterization and regulation of angiotensin II receptors in rat adipose tissue. Angiotensin receptors in adipose tissue. Adv Exp Med Biol 1996, 396:39-47.
27. Cassis LA, Saye J, Peach MJ: Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988, 11:591-596.
28. Davy KP: The global epidemic of obesity: are we becoming more sympathetic? Curr Hypertens Rep 2004, 6:241-246.
29. Peterson LR, Herrero P, Schechtman KB, et al.: Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004, 109:2191-2196.
30. Zhou YT, Grayburn P, Karim A, et al.: Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000, 97:1784-1789.
31. Aasum E, Hafstad AD, Severson DL, Larsen TS: Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 2003, 52:434-441.
32. Knuuti J, Takala TO, Nagren K, et al.: Myocardial fatty acid oxidation in patients with impaired glucose tolerance. Diabetologia 2001, 44:184-187.
33. Turpeinen AK, Takala TO, Nuutila P, et al.: Impaired free fatty acid uptake in skeletal muscle but not in myocardium in patients with impaired glucose tolerance: studies with PET and 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid. Diabetes 1999, 48:1245-1250.
34. Turpeinen AK, Kuikka JT, Vanninen E, Uusitupa MI: Abnormal myocardial kinetics of 123I-heptadecanoic acid in subjects with impaired glucose tolerance. Diabetologia 1997, 40:541-549.
35. Chiu HC, Kovacs A, Ford DA, et al.: A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001, 107:813-822.
36. Listenberger LL, Han X, Lewis SE, et al.: Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003, 100:3077-3082.
37. Blendea MC, Jacobs D, Stump CS, et al.: Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 2005, 288:E353-E359.
38. Chiu HC, Kovacs A, Blanton RM, et al.: Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 2005, 96:225-233.
39. Lee Y, Naseem RH, Park BH, et al.: Alpha-lipoic acid prevents lipotoxic cardiomyopathy in acyl CoA-synthase transgenic mice. Biochem Biophys Res Commun 2006, 344:446-452.
40. Alpert MA, Terry BE, Mulekar M, et al.: Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol 1997, 80:736-740.
41. Karason K, Wallentin I, Larsson B, Sjostrom L: Effects of obesity and weight loss on cardiac function and valvular performance. Obes Res 1998, 6:422-429.
42. Kanoupakis E, Michaloudis D, Fraidakis O, et al.: Left ventricular function and cardiopulmonary performance following surgical treatment of morbid obesity. Obes Surg 2001, 11:552-558.
43. Himeno E, Nishino K, Okazaki T, et al.: A weight reduction and weight maintenance program with long-lasting improvement in left ventricular mass and blood pressure. Am J Hypertens 1999, 12:682-690.
44. Harp JB, Henry SA, DiGirolamo M: Dietary weight loss decreases serum angiotensin-converting enzyme activity in obese adults. Obes Res 2002, 10:985-990.
45. Willens HJ, Chakko SC, Byers P, et al.: Effects of weight loss after gastric bypass on right and left ventricular function assessed by tissue Doppler imaging. Am J Cardiol 2005, 95:1521-1524.
46. Peterson LR, Mohammed BS, Avidan M, et al.: Moderate weight loss decreases myocardial oxygen consumption and cardiac work in obese men and women [abstract]. J Am Coll Cardiol 2006, 47:105A.
47. Backman L, Freyschuss U, Hallberg D, Melcher A: Cardiovascular function in extreme obesity. Acta Med Scand 1973, 193:437-446.
48. Backman L, Freyschuss U, Hallberg D, Melcher A: Reversibility of cardiovascular changes in extreme obesity. Effects of weight reduction through jejunoileostomy. Acta Med Scand 1979, 205:367-373.
49. Hallsten K, Virtanen KA, Lonngvist F, et al.: Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone. Diabet Med 2004, 21:1280-1287.
50. Randle PJ, Newsholme EA, Garland PB: Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 1964, 93:652-665.